This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Align Technology (ALGN) Beats on Earnings and Revenues in Q1
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.
Medical Product Stock Earnings Roster for Apr 25: LH & More
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.
Should You Buy Align Technology (ALGN) Ahead of Earnings?
by Zacks Equity Research
Given that Align Technology (ALGN) has a favorable Zacks Rank and a positive ESP, investors might want to consider this stock ahead of earnings.
Factors Setting Stage for CVS Health's (CVS) Q1 Earnings
by Zacks Equity Research
CVS Health (CVS) expects robust 2018 PBM selling season and strong Pharmacy Services segment to drive earnings in Q1.
Can ResMed (RMD) Repeat Stable Device Growth in Q3 Earnings?
by Zacks Equity Research
ResMed's (RMD) sleep apnea patient volume consistently witnesses a steady expansion. We expect this upside to continue in the fiscal third quarter as well.
Quest Diagnostics (DGX) Q1 Earnings Meet, Guidance Intact
by Zacks Equity Research
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q1 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Can Steady Overall Growth Drive Align's (ALGN) Q1 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is likely to gain from strength in the Invisalign space as well as Scanner and Service business in Q1.
Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained
by Zacks Equity Research
Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.
Henry Schein Ties Up With Internet Brands to Boost Dental Arm
by Zacks Equity Research
Henry Schein (HSIC) banks on part of its strategic plan, digital dentistry. In this regard, its latest joint venture with Internet Brands buoys optimism.
Zacks.com featured highlights include: Amazon.com, Align, Axon Enterprise, Antero and Jones Lang
by Zacks Equity Research
Zacks.com featured highlights include: Amazon.com, Align, Axon Enterprise, Antero and Jones Lang
Company News For April 6, 2018
by Zacks Equity Research
Companies In The News are: MON,BAYN,GMS,CYOU,ALGN
Get Earnings Surprise From 5 Top Stocks & Beat Market Blues
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next releases.
Align Unveils Vivera Retainers for Deep Bite Correction
by Zacks Equity Research
Align (ALGN) hopes to taste greater clinical success in the orthodontic space with Vivera Retainers' integration into Precision Bite Ramps, which are part of the company's Invisalign G5.
Align Technology Broadens Invisalign Suite, Extends Reach
by Zacks Equity Research
Align Technology (ALGN) leaves no stone unturned to boost the Invisalign product portfolio and strengthen its hold in the high-potential invisible orthodontics market.
Myriad Genetics' BRACAnalysis Test Platform Gets PMA in Japan
by Zacks Equity Research
Myriad Genetics (MYGN) leaves no stone unturned to boost uptake of BRACAnalysis test and strengthen the Molecular Diagnostics portfolio.
Ensign Group Boosts Arizona Base With Real Estate Buyout
by Zacks Equity Research
Ensign Group's (ENSG) inclination toward inorganic growth leads to numerous acquisitions, significantly favoring the company's top line.
Boston Scientific to Acquire Securus Medical, Boost EP Unit
by Zacks Equity Research
Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.
Dental Implant & Prosthetic Boom Puts Spotlight on 3 Stocks
by Gargi Seth
The dental market has outperformed the broader market in last ten years on the back of demand from both teenagers and adults.
Will Walgreens' (WBA) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Walgreens Boots' (WBA) increase in sales at the Retail Pharmacy International segment, on account of the company's strategic tie-ups, along with strength in other businesses buoy optimism.
Align Technology Banks on Global Growth, Competition Rife
by Zacks Equity Research
We are encouraged by Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in Asia Pacific.
Align Technology (ALGN) Q4 Earnings Top on Invisalign Sales
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from the Clear Aligner as well as Scanner and Service segments in Q4.
Post-Market Q4 Earnings Parade: SFLY, ALGN & More
by Mark Vickery
Following today's closing bell, we see fresh quarterly earnings results from a host of new companies.
Can Invisalign Drive Align Technology's (ALGN) Q4 Earnings?
by Zacks Equity Research
Align Technology (ALGN) poised to gain from strength in the Invisalign space as well as Scanner and Service business in Q4.
Align Rides on Balanced Segmental Growth Amid Stiff Contest
by Zacks Equity Research
Align (ALGN) gains from balanced sales growth across all its channels of late, primarily on high InvisAlign Technology case volumes.
Universal Health Grows Inorganically, Rising Costs a Drag
by Zacks Equity Research
Universal Health's (UHS) top line grows on solid Acute Care and Behavioral Health platforms. Nevertheless, surging level of debt bothers.